VitaPath Genetics is developing clinically validated molecular diagnostics for disease-linked genetic mutations, which can be safely and easily corrected. The company’s first saliva-based assay identifies women with an elevated risk of having a baby with Spina Bifida, a common debilitating birth defect that can be prevented with high dose, prescription folic acid under the care of a physician. VitaPath Genetics’ discovery platform is being used to build a robust pipeline of follow-on products for maternal/fetal health and other metabolic diseases. The company’s goal is to safely reduce the incidence of preventable disease and lower system costs.